Innate Pharma S.A. Gains 20.87%
Innate Pharma S.A. (IPHA:NASDAQ) shot up at $3.07, representing a gain of 20.9%. On Fri, Sep 16, 2022, IPHA:NASDAQ touched a New 2-Week High of $3.07. The stock got featured on our News Catalysts scanner on Thu, Sep 15, 2022 at 03:18 AM in the 'EARNINGS' category. From Fri, Sep 02, 2022, the stock recorded 55.56% Up Days and 30.00% Green Days
About Innate Pharma S.A. (IPHA:NASDAQ)
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
Top 10 Gainers:
- Panbela Therapeutics Inc. (PBLA:NASDAQ), 53.03%
- Applied Optoelectronics, Inc. (AAOI:NASDAQ), 50.4%
- iBio, Inc. (IBIO:NYSEMKT), 49.84%
- Armata Pharmaceuticals Inc. (ARMP:NYSEMKT), 31.15%
- Axcella Health Inc. (AXLA:NASDAQ), 29.57%
- Anixa Biosciences, Inc. (ANIX:NASDAQ), 27.46%
- Lannett Company, Inc. (LCI:NYSE), 25.1%
- Integrated Media Technology Limited (IMTE:NASDAQ), 21.53%
- Innate Pharma S.A. (IPHA:NASDAQ), 20.87%
- TMC the metals company Inc. (TMC:NASDAQ), 20.19%